Global In Vitro Lung Model Market is Estimated to Witness High Growth Owing to Advancements in 3D Organoid Technology
In vitro lung models are biological systems that mimic the structure and function of human lungs. These models are being employed as replacements for animal testing and help better understand human lung biology and toxicity of drugs, chemicals, and nanomaterials. Advances in 3D organoid technology have allowed scientists to develop lab-grown miniaturized lung organoids that more closely replicate the complexity of actual human lungs compared to traditional 2D cell culture models.
The Global In Vitro Lung Model Market is estimated to be valued at US$ 245.0 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Global In Vitro Lung Model Market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited.
The key opportunities in the market include increased funding for research on respiratory diseases and development of advanced disease models to replicate lung pathologies like cancer, fibrosis, asthma etc.
Technological advancements like development of microfluidic organ-on-a-chip platforms and application of stem cell-derived lung organoids have improved physiological relevance of in vitro lung models.
Market drivers
Stringent regulations replacing animal testing is a major driver for the in Global In Vitro Lung Model Market Size . Regulatory agencies like the EU, FDA are promoting the 3R approach – reduce, replace and refine the use of animals in toxicity testing. In vitro lung models offer a human-relevant alternative to animal testing for evaluating safety and efficacy of drugs, chemicals and nanomaterials inhaled through the lung route. This is expected to significantly drive the adoption of these advanced lung models over the forecast period.
Global In Vitro Lung Model Market
Current challenges in the Global In Vitro Lung Model Market:
Lack of validated and standardized preclinical in vitro lung models: The existing lung models often lack scalability, translatability and clinical predictability. They fail to capture the complexity of in vivo lung physiology. This poses challenge for drug development and toxicity screening applications.
High costs associated with 3D lung models: Constructing sophisticated 3D lung models with multi-cellular complexity and ability to replicate key lung functions is technically challenging. It requires latest cell culture techniques and microfluidic organ-on-chip systems which are currently highly expensive.
SWOT Analysis
Strength: The 3D lung models offer more realistic physio-anatomical structure and particle deposition compared to conventional 2D cell cultures. They better mimic lung tissue microenvironment and physiology.
Weakness: The lung models currently have low-throughput nature and lack standardized evaluation methods. This poses challenges in validating clinical relevance and regulatory acceptance.
Opportunity: Growing implementation of microfluidic organ-on-a-chip technology provides opportunity to develop dynamic multi-organ linked lung models with improved predictability.
Threats: High dependence on primary human cells and tissues poses challenges in maintaining consistent quality and performance of the lung models.
North America region holds the major share in the global in vitro lung model market, both in terms of value and volume. High adoption of advanced preclinical models for drug development and regulatory mandates for alternative testing methods have boosted the market in the region.
Asia Pacific is projected to witness the fastest growth during the forecast period. Expanding biopharmaceutical industry, increasing government support for developing alternative methods to animal testing, and rising healthcare expenditure in countries like China and India are some key factors driving the APAC market.
Global In Vitro Lung Model Market
Current challenges in the Global In Vitro Lung Model Market:
Lack of validated and standardized preclinical in vitro lung models: The existing lung models often lack scalability, translatability and clinical predictability. They fail to capture the complexity of in vivo lung physiology. This poses challenge for drug development and toxicity screening applications.
High costs associated with 3D lung models: Constructing sophisticated 3D lung models with multi-cellular complexity and ability to replicate key lung functions is technically challenging. It requires latest cell culture techniques and microfluidic organ-on-chip systems which are currently highly expensive.
SWOT Analysis
Strength: The 3D lung models offer more realistic physio-anatomical structure and particle deposition compared to conventional 2D cell cultures. They better mimic lung tissue microenvironment and physiology.
Weakness: The lung models currently have low-throughput nature and lack standardized evaluation methods. This poses challenges in validating clinical relevance and regulatory acceptance.
Opportunity: Growing implementation of microfluidic organ-on-a-chip technology provides opportunity to develop dynamic multi-organ linked lung models with improved predictability.
Threats: High dependence on primary human cells and tissues poses challenges in maintaining consistent quality and performance of the lung models.
North America region holds the major share in the global in vitro lung model market, both in terms of value and volume. High adoption of advanced preclinical models for drug development and regulatory mandates for alternative testing methods have boosted the market in the region.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
